RF Acquisition Corp II

RFAI$58+355.62%

RF Acquisition Corp II (NASDAQ: RFAI) is experiencing a massive surge today, August 21, 2026, with shares skyrocketing by hundreds of percentage points in pre-market and early trading. The core reason for this significant upward volatility is the overwhelming shareholder approval of its proposed business combination with Nanyang Biologics Pte. Ltd., an AI-driven drug discovery company based in Singapore.

On August 19, 2026, RFAI shareholders convened an extraordinary general meeting, where they decisively approved all six proposals related to the merger. These approvals, detailed in subsequent SEC filings on August 20, 2026, effectively removed the final governance and structural hurdles for the de-SPAC transaction, paving the way for the combined entity to trade on Nasdaq under the expected ticker "NYB."

A critical amplifying factor behind the extreme price action is the low-float dynamic resulting from substantial share redemptions. Preliminary redemption requests accounted for approximately 3.96 million ordinary shares, representing about 47.4% of the shares outstanding. This significant reduction in the public float, post-redemption, dramatically amplifies buying pressure and speculative interest, leading to the exaggerated price spikes observed today. While short interest has seen a recent increase, it remains relatively low and is not the primary driver of this volatility; rather, the merger approval combined with tight float dynamics is the direct catalyst.

Werewolf Therapeutics Inc

HOWL$0.87+102.57%

Werewolf Therapeutics (HOWL) shares surged over 120% today, August 21, 2026, primarily due to the announcement of a definitive merger agreement with privately held Ambros Therapeutics and a concurrent oversubscribed $150 million private placement. This strategic move effectively transforms Werewolf, which had been exploring alternatives due to a shrinking cash runway, into a well-funded, late-stage biotechnology company.

The core reason for the massive positive market reaction stems from the combined entity's new focus on Ambros Therapeutics' lead program, neridronate, for Complex Regional Pain Syndrome Type 1 (CRPS-1). Neridronate is a non-opioid pain treatment currently in a pivotal Phase 3 clinical trial (CRPS-RISE) and holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. Importantly, there are no FDA-approved treatments for CRPS-1, an orphan disease affecting 50,000 to 70,000 new U.S. patients annually. The $150 million financing ensures a cash runway into the first half of 2029, funding the company through Phase 3 topline results (expected in 2028) and a planned New Drug Application submission. Investors are reacting positively to this shift from a cash-constrained immunotherapy pipeline to a late-stage program targeting a significant unmet medical need with substantial market exclusivity potential through 2045. Despite existing Werewolf shareholders retaining only approximately 6.8% of the combined company, the improved financial stability and clear development pathway for a promising drug candidate are driving the substantial increase.

StableCoinX Inc

USDE$7.41+85.25%

StablecoinX Inc. (Nasdaq: USDE) is experiencing significant upward volatility today, primarily driven by positive developments within the Ethena digital dollar ecosystem, which forms the core of its investment strategy. While the provided headline notes that StablecoinX (USDE) booked a $34.6 million loss for the fiscal quarter ended June 30, 2026, and holds a $212.9 million ENA treasury, this loss reflects past performance and was reported on August 14, 2026.

The dramatic fluctuation today stems directly from Ethena, the issuer of the USDe synthetic dollar and the ENA governance token. Ethena recently announced a substantial $1 billion overcollateralized institutional lending facility with FalconX, unveiled between August 19-21, 2026. This strategic partnership diversifies USDe's reserve yield strategies beyond traditional crypto basis trades, providing new, more stable revenue streams.

Consequently, the ENA governance token, of which StablecoinX Inc. holds approximately 3 billion tokens (representing about 20% of the circulating supply), has surged dramatically, with reports indicating a price increase of 45-65% in the past week. As StablecoinX’s valuation is inherently tied to its substantial ENA holdings, the significant appreciation of ENA directly translates into a sharp rise in the USDE stock price today, overshadowing the previously reported quarterly loss. The market is reacting to the bolstered confidence and expanded utility for the underlying Ethena ecosystem, leading to a strong bullish momentum for StablecoinX.

Sadot Group Inc

SDOT$13.18+56.16%

Sadot Group (SDOT) is experiencing a significant surge today, primarily driven by a high-volume speculative breakout fueled by the company's recent strategic shift towards AI-powered commodity trading technology. The market is reacting positively to Sadot Group's expansion into AI trading tools, including a recent agreement to acquire $6 million in intellectual property for its TradeOS risk-management platform. This pivot marks a significant change from its traditional focus on the global food supply chain.

Adding to the volatility and amplifying the upward momentum is the stock's tight float, a direct consequence of a 1-for-20 reverse stock split executed on May 29, 2026. With fewer shares available for trading, even modest increases in buying volume can trigger sharp intraday price swings.

Concurrently, Sadot Group has undertaken several financing actions, including the recent settlement of a $271,739 debenture by issuing 33,968 common shares, as well as prior debt-to-equity settlements totaling $4.3 million. While these actions aim to improve the balance sheet and have secured key holder consents, the issuance of shares to settle debt and the subsequent anti-dilution adjustments to other convertible notes introduce further dilution risk for existing shareholders, a factor that typically exerts downward pressure. However, the immediate speculative interest in the AI pivot and the low share count appear to be overriding these dilutive concerns for today's market action.

Knorex Ltd

KNRX$0.51+54.91%

KNOREX Ord Shs Class A (KNRX) has experienced significant volatility today, primarily driven by a delayed reaction to its recently released 2025 fiscal year financial results and the resolution of a critical regulatory compliance issue. On August 19, 2026, the company finally reported its long-overdue financial results for the fiscal year ended December 31, 2025. These results were overwhelmingly negative, showing a substantial 44.2% decline in revenue to $6.0 million from $10.8 million in the prior year, alongside a net loss that widened to $11.5 million from $5.9 million in 2024. The company also reported critically low cash and cash equivalents of $129,000 as of December 31, 2025.

Despite these dismal financial fundamentals, the stock has shown a sharp upward movement, with reports indicating a +26.67% increase on August 21st. This seemingly counterintuitive rally can be attributed to the market reacting to the *removal of uncertainty* rather than the poor underlying numbers. KNRX had previously received a notice from NYSE American on May 22, 2026, regarding its non-compliance with listing standards due to the delayed filing of its 2025 annual report. The completion of this crucial filing, albeit with negative figures, effectively resolves the immediate threat of delisting and provides clarity to investors.

Furthermore, the stock has exhibited high volatility, being more volatile than 90% of American stocks over the past three months. Leading up to the financial report, KNRX also saw a massive increase in short interest (over 2200% change by mid-July), indicating a significant number of bearish bets against the company. The resolution of the regulatory overhang, combined with the stock's inherent volatility and elevated short interest, likely triggered a short squeeze, forcing short sellers to cover their positions and driving the price sharply higher despite the underlying operational and financial weaknesses. The substantial negative equity and liquidity challenges remain significant long-term concerns for KNRX.

AIAI Holdings Corp

AIAI$6.62+46.14%

AIAI Holdings (AIAI) experienced a significant surge of approximately 39.5% on Friday, August 21, 2026. While the news headline "AIAI Holdings (AIAI) director adds 5,000 new shares" provides a positive signal of insider confidence, it is part of a broader catalyst driving this substantial daily fluctuation. Director Eric Affeldt purchased 5,000 shares on August 19, 2026, at $5.96 per share. This was complemented by purchases from CEO Todd Anthony Furniss (1,000 shares) and Director Remy Donald Michael (905 shares) around the same period.

However, the primary driver for such an abrupt upward movement stems from the company's reaffirmed strategic AI-led growth initiatives and recent operational achievements, which appear to be overshadowing its reported Q2 2026 net loss of $38.9 million on August 14, 2026. Recent reports indicate that AIAI Holdings' stock action has been propelled by "strategic AI-led growth news rather than pure market volatility". Specifically, a teaming agreement outlined by Messier 42 is expected to generate "substantial near-term EBITDA and free cash flow". Additionally, the commercial launch of Dôr Retail Intelligence by Constellation Network and MediGuide's Longevity Intelligence Service in August 2026 highlight the company's commitment to embedding transformational AI across its portfolio. The combination of these forward-looking growth narratives, tangible product launches, and strong insider buying signals from multiple executives has likely fueled the market's enthusiasm, leading to Friday's sharp price appreciation. The stock's inherent high volatility also amplifies such movements.

Exyn Technologies Inc

EXYN$2.21+39.87%

The significant fluctuation in Exyn Technologies (EXYN) stock today stems from a confluence of severe negative developments, primarily corporate governance failures and critical financial instability. The core driver is the immediate resignation of CEO Brandon Torres Declet following an internal investigation that uncovered $287,000 in unauthorized personal spending using a company credit card, as disclosed in a revised quarterly financial report. This serious breach of fiduciary duty and corporate ethics fundamentally erodes investor trust and raises alarm bells regarding the company's internal controls and integrity. The company is actively seeking repayment of these funds.

Compounding this leadership scandal are dire financial disclosures. Concurrently with the CEO's departure, Exyn Technologies reported its second-quarter 2026 financial results, revealing a decline in revenue and a widening net loss. More critically, management explicitly stated that its current cash resources are insufficient to fund operations for the next 12 months, casting "substantial doubt about going concern". This signals profound operational and financial distress, prompting a sharp sell-off as investors re-evaluate the company's viability. While an interim CEO has been appointed, the immediate market reaction reflects deep concern over these combined regulatory, governance, and financial headwinds, driving considerable volatility and a downward price trend since its May IPO.

Lisata Therapeutics Inc

LSTA$1.55+38.39%

Lisata Therapeutics, Inc. (LSTA) experienced a significant surge of 16.4% today, reaching $1.3 per share during Friday's regular session. This substantial upward movement is primarily driven by the announcement from Kuva Labs, Inc. of its intention to submit a *new, fully funded offer* to acquire Lisata Therapeutics no later than August 31, 2026.

This development re-energized investor confidence following the termination of a previous merger agreement between the two companies on August 4, 2026, which led to Lisata filing a lawsuit against Kuva Labs for breach of contract and seeking a $2 million termination fee. The prior termination was attributed to Kuva's inability to secure necessary financing. Kuva Labs' current declaration of a "fully funded" offer directly addresses this past financing hurdle, providing a renewed and tangible acquisition prospect for Lisata's shareholders. Despite Lisata's recent workforce reduction of approximately 72% to conserve cash and explore strategic alternatives after the initial deal collapsed, the prospect of a confirmed acquisition, backed by a commitment of full funding, has served as the immediate and core catalyst for today's sharp positive price action.

AMC Robotics Corp

AMCI$6.69+36.53%

AMC Robotics Corp (AMCI) has experienced significant volatility in its stock price primarily due to recent capital-raising activities through warrant inducement agreements, set against a backdrop of ongoing financial challenges and a history of shareholder dilution. On August 17, 2026, an 8-K filing detailed that AMC Robotics entered into agreements with two existing warrant holders. These holders agreed to immediately exercise existing warrants at a reduced price of $1.65 per share (a significant discount from the previous $4.017) to raise $1 million in gross proceeds for the company. They also have an option to exercise additional warrants for up to another $1.1 million within 30 trading days. In exchange, AMC Robotics issued new inducement warrants to purchase up to 1,219,816 shares at a higher exercise price of $5.7756 per share, exercisable immediately and with a four-and-one-third-year expiration.

The proceeds from these exercises are earmarked for critical needs, including funding its robotics manufacturing facility in Vietnam, working capital, and general corporate purposes. While securing capital is positive, the market reacted with a moderate decline of 2.04% on August 21, 2026, following the announcement of the closing of these transactions. This negative reaction suggests that investors are likely factoring in the dilutive effect of issuing new warrants and the discounted exercise of existing ones, particularly given the company's prior history of substantial shareholder dilution and concerning financial fundamentals, such as negative profit margins and high liabilities. Therefore, the volatility is a direct consequence of these capital restructuring efforts aimed at shoring up the balance sheet, but at a cost of potential further dilution.

The9 Limited ADR

NCTY$5.78+32.57%

The significant upward fluctuation in The9 (NASDAQ: NCTY) stock today is primarily driven by the advancement of its investee, Nanyang Biologics (NYB), towards a Nasdaq listing. Shareholders of RF Acquisition Corp II (RFAI) approved NYB's proposed business combination at an extraordinary general meeting on August 19, 2026, marking a crucial step for NYB to list on Nasdaq under the ticker "NYB". Upon the completion of this transaction, The9 anticipates holding approximately a 15%–16% stake in the combined Nasdaq-listed AI drug discovery company.

This development is perceived by The9 as a strategic diversification, extending its reach beyond its core AI-powered gaming ecosystem into the broader and highly promising AI-driven life sciences sector, specifically drug discovery. The market has reacted strongly and positively to this news, with NCTY gaining 25.46% and experiencing significantly high trading volume (3.7 times its average) on August 21, 2026. While The9 has historically reported net losses and negative cash flows in recent years, it did achieve a record quarterly profit in Q1 2026, partly due to digital asset income. The current low short interest (around 1-1.42%) suggests that today's sharp rise is fundamentally news-driven rather than a short squeeze.